Innovent Biopharmaceutical Transformation
Innovent: Transforming From a China Leading Biopharmaceutical
Company to a Global Premier Player
XIX
Innovent
Fully Integrated
Biopharmaceutical Platform
World-class discovery, development,
manufacturing and commercialization
capabilities
60,000L production capacity, one of the
largest in China
• Strong commercialization capability with
a commercial team of ~3,000 people
Comprehensive Global
Collaborations
Continued collaborations with global
pharmaceutical and biotech companies
Established an integrated platform with
validated capabilities, striving to be the
best choice for our partners
阿达水单抗注射液
Innovent
达伯舒
达攸同
苏立信®
达伯华 ® 逹伯坦
利妥昔单抗注射液
Pemazyre (tablets)
耐立克 9
奥雷巴替尼 olverembatinib
CYRAMZA™
ramucirumab injection
10 mg/mL solution
Confidential
Copyright©2022 Innovent
Robust Pipeline in Both
Oncology and Non-oncology
• Robust pipeline across novel
therapeutics in both oncology and non-
oncology
7 commercialized, 1 NDA, 5 in pivotal
trials and 18 in clinical stage
*
Global R&D Organization and
Footprint
Global R&D platform with 1,500 talents
in China, US and Europe
• Innovent Academy as a powerful
discovery engine to nourish global FIC and
BIC products
25
25View entire presentation